Pharmaceuticals

Gastric Cancer Therapy Market Performance Outlook 2026–2030: Revenue to Hit $6.96 Billion at 9.1% CAGR

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the gastric cancer therapy market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Gastric Cancer Therapy Market between 2026 and 2030?

The gastric cancer therapy market has experienced robust expansion in recent years. Projections indicate its size will expand from $4.5 billion in 2025 to reach $4.92 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. This historical growth is attributable to factors such as restricted access to targeted therapies, a dependence on traditional chemotherapy and surgical interventions, the rising incidence of gastric cancer, the expansion of hospital oncology infrastructure, and heightened recognition of early detection initiatives.

The gastric cancer therapy market size is anticipated to exhibit robust expansion in the upcoming years, projected to reach $6.96 billion in 2030, growing at a compound annual growth rate (CAGR) of 9.1%. This projected growth is driven by the emergence of novel immunotherapies and checkpoint inhibitors, increasing adoption of precision medicine, the expansion of outpatient oncology services, heightened investment in gastric cancer research, and the integration of digital health tools for patient monitoring. Significant trends expected during this forecast period include a greater embrace of targeted and personalized therapies, a rise in the use of combination therapy approaches, the growth of early detection and screening programs, an expansion of home care and ambulatory treatment options, and a dedicated focus on minimizing adverse effects and improving patients’ quality of life.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25767&type=smp

Which Drivers Are Expected To Impact The Gastric Cancer Therapy Market During The Forecast Period?

The increasing occurrence of helicobacter pylori infection is projected to fuel the expansion of the gastric cancer therapy market in the future. This bacterial infection primarily targets the stomach lining and stands as a major contributor to both chronic gastritis and gastric cancer. The heightened incidence of helicobacter pylori infection largely stems from inadequate sanitation, given that insufficient hygiene and polluted food or water enable the bacteria’s oral-oral or fecal-oral spread. Gastric cancer therapy assists in mitigating the risk of gastric cancer linked to helicobacter pylori infection. It achieves this by treating the infection, lessening related gastric inflammation and cell damage, and halting the advancement of chronic gastritis and atrophic changes that could result in malignant transformation of the gastric lining. For example, a report released by the Government of Canada, a Canada-based government administration, in November 2024 indicated that as of January 2023, the recurrence rate for H. pylori infection was projected to be as high as 19%, though it fluctuates with geographical area and age. Consequently, the growing occurrence of helicobacter pylori infection is stimulating expansion within the gastric cancer therapy market.

Which Segments Are Driving Activity In The Gastric Cancer Therapy Market?

The gastric cancer therapy market covered in this report is segmented –

1) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

2) By Drug Class: Cytotoxic Agents, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, Miscellaneous Agents

3) By Administration Route: Oral, Intravenous, Intramuscular, Subcutaneous

4) By Stage of Disease: Early Stage, Locally Advanced Stage, Metastatic Stage

5) By End User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Research Institutions, Home Care Settings

Subsegments:

1) By Chemotherapy: Neoadjuvant Chemotherapy (NAC), Adjuvant Chemotherapy (AC), Palliative Chemotherapy (PC), Combination Chemotherapy, Monotherapy

2) By Targeted Therapy: Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy, Vascular Endothelial Growth Factor (VEGF) Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Mesenchymal-Epithelial Transition (MET) Inhibitors, Claudin 18 Isoform 2 Inhibitors

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer, Cytokine Therapy, Combination Immunotherapy

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Three-Dimensional Conformal Radiation Therapy (3D-CRT), Brachytherapy

5) By Surgery: Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Subtotal Gastrectomy, Total Gastrectomy, Lymphadenectomy

How Are Emerging Trends Affecting The Progression Of The Gastric Cancer Therapy Market?

Major companies operating in the gastric cancer therapy market are concentrating on developing novel treatments, such as combination approaches, to enhance treatment effectiveness and patient outcomes. This type of therapy involves utilizing two or more treatments, including chemotherapy, targeted therapy, or immunotherapy, in conjunction to boost overall efficacy. For instance, in December 2024, BeOne Medicines Ltd., a China-based pharmaceutical company formerly known as BeiGene, secured approval from the U.S. Food and Drug Administration (FDA) for Tevimbra (tislelizumab-jsgr) when combined with platinum- and fluoropyrimidine-based chemotherapy. This approval is for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express PD-L1 (=1). The authorization stemmed from data from the Phase 3 RATIONALE-305 trial, which revealed that the combination therapy substantially improved median overall survival to 15.0 months, in contrast to 12.9 months with chemotherapy alone, marking a 20% reduction in the risk of death. This significant event underscores an evolving trend among leading pharmaceutical firms to invest in innovative, multimodal treatment strategies that integrate immunotherapy with traditional chemotherapy regimens to better clinical outcomes, delay disease progression, and improve survival rates for patients with advanced gastric cancer.

Which Key Market Players Are Investing In Expansion And Innovation Within The Gastric Cancer Therapy Market?

Major companies operating in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-therapy-global-market-report

Which Regions Are Poised For Strategic Growth In The Gastric Cancer Therapy Market?

North America was the largest region in the gastric cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gastric Cancer Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25767&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Therapy Market 2026, By The Business Research Company

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Cancer Diagnostic Procedure Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-procedure-global-market-report

Intestine Cancer Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795